Working… Menu

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03923478
Recruitment Status : Terminated (Sponsor Decision)
First Posted : April 22, 2019
Last Update Posted : March 19, 2021
Information provided by (Responsible Party):
Assembly Biosciences

Brief Summary:
Phase 1B randomized, double-blind, placebo-controlled, two-cohort clinical trial of ABI-M201 in adult subjects with mildly-to-moderately active Ulcerative Colitis(UC) and ongoing treatment with mesalamine.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Chronic Mild Ulcerative Colitis Chronic Moderate Drug: ABI-M201 Drug: Placebo Phase 1

Detailed Description:
This multi-center randomized, double-blind, placebo-controlled study will evaluate the safety of ABI-M201 and its effects on disease activity measures in men and women with mildly-to-moderately active UC and ongoing treatment with mesalamine. The study will consist of 2 sequential, non-overlapping participant cohorts, separated by intervening interim analysis (IA). Both cohorts will involve 8-weeks of study drug treatment. Interim data from the initial treatment cohort (Cohort A) will inform decision to advance to the subsequent second cohort (Cohort B) and its dose selection. 20 subjects will be randomized to cohort A (1:1 allocation) and receive treatment with 1 capsule per day of ABI-M201 versus Placebo. 24 subjects will be randomized to cohort B (3:1 allocation) and receive treatment with up to 5 capsules one time a day of ABI-M201 versus Placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double blind, placebo-controlled trial involving two sequential non-overlapping cohorts, with intervening interim analysis
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, Efficacy and Mircobiological Response of Oral ABI-M201 in Subjects With Mildly-to-Moderately Active UC With Ongoing Mesalamine Treatment
Actual Study Start Date : June 24, 2019
Actual Primary Completion Date : January 20, 2021
Actual Study Completion Date : January 20, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ABI-M201

Cohort A: 1 capsule one time a day

Cohort B: 1- 5 capsules one time a day

Drug: ABI-M201
Active Treatment

Placebo Comparator: Placebo

Cohort A: 1 capsule one time a day

Cohort B: 1-5 capsules one time a day

Drug: Placebo
Control Treatment

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 8-weeks ]

  2. Incidence of Treatment-Emergent Laboratory Abnormalities [ Time Frame: 8-weeks ]

Secondary Outcome Measures :
  1. Clinical Remission [ Time Frame: 8-weeks ]
    [UC Disease Activity]

  2. Endoscopic Improvement [ Time Frame: 8-weeks ]
    [UC Disease Activity]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Established diagnosis of UC for at least 3 months prior to screening, with minimum disease extent of 15 cm from the anal verge
  • Mildly to moderately active UC
  • Inadequate response to ongoing treatment with oral mesalamine ≥2.4 g/day for ≥4 weeks from screening visit

Exclusion Criteria:

  • Possible or confirmed diagnosis of Crohn's Disease or other forms of inflammatory bowel disorders
  • Ongoing or failed prior treatment for UC with methotrexate, azathioprine, 6-mercaptopurine, cyclosporine, tofacitinib, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, tacrolimus (FK-506), or biologics (e.g., TNF-alpha-antagonists, anti-integrin therapies, or agents targeting IL-12 or IL-23, etc.)
  • Any immunosuppressive condition or treatment with immunosuppressive medications
  • History of prior surgical intervention in any region of the gastrointestinal tract (excluding minor surgery)
  • Prior diagnosis of any cardiovascular, renal, hepatic, endocrine, infectious, hematological, oncologic, neuro-psychiatric or immune-mediated disorder, which in the opinion of the Principal Investigator might impact the subject's safety or compliance, or the interpretation of results
  • Treatment with any other investigational drugs ≤12 weeks prior to baseline visit
  • The participant has a condition or is in a situation which, in the Principal Investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03923478

Layout table for location information
United States, California
(Investigator site)
Oakland, California, United States, 94612
(Investigator Site)
San Carlos, California, United States, 94070
United States, Georgia
(Investigator Site)
Decatur, Georgia, United States, 30033
United States, Louisiana
(Investigator Site)
Shreveport, Louisiana, United States, 71105
United States, Michigan
(Investigator Site)
Chesterfield, Michigan, United States, 48047
(Investigator Site)
Ypsilanti, Michigan, United States, 48197
United States, Minnesota
(Investigator Site)
Rochester, Minnesota, United States, 55905
United States, Tennessee
(Investigator Site)
Jackson, Tennessee, United States, 38305
United States, Washington
(Investigator Site)
Bellevue, Washington, United States, 98004
United States, Wisconsin
(Investigator Site)
Milwaukee, Wisconsin, United States, 53226
Canada, Ontario
(Investigator site)
Sudbury, Ontario, Canada, P3C 5K6
Sponsors and Collaborators
Assembly Biosciences
Layout table for additonal information
Responsible Party: Assembly Biosciences Identifier: NCT03923478    
Other Study ID Numbers: ABI-M201-101
First Posted: April 22, 2019    Key Record Dates
Last Update Posted: March 19, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assembly Biosciences:
Phase 1B
Placebo Controlled
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases